Abstract 1526P
Background
The nab-paclitaxel plus gemcitabine (AG) is the standard first-line chemotherapy of advanced pancreatic cancer with limited efficacy. Dual inhibition of PD-L1 and TGF-β is a promising therapeutic strategy, as the key pathways have independent and complementary immunosuppressive functions. SHR-1701 is a bi-functional agent which can simultaneously block both the PD-1/PD-L1 and TGF-β/TGF-βR signaling within the TME. Until now, it is obscure for the clinical value of SHR1701 in pancreatic cancer. This phase 1b/2 clinical trial was designed to evaluate the antitumor activity and safety of SHR-1701 combined with AG chemotherapy regimen in patients with previously untreated locally advanced and metastatic pancreatic cancer.
Methods
Patients received SHR-1701 (30 mg/kg) on day 1 plus gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) on day 1 and 8 of each 3-week cycle by intravenous infusion. The primary endpoint of phase 1b part was recommended phase 2 dose (RP2D). In the phase 2 part, the primary endpoint was objective response rate (ORR) per investigator according to RECIST v1.1.
Results
No dose-limiting toxicities (DLTs) were observed among the first 6 patients; the RP2D of SHR-1701 was 30 mg/kg. As of Mar 31, 2023, 56 patients were enrolled. Median follow-up was 10.3 months (range, 0.2-24.7). ORR was 32.1% (95% CI, 20.3-46.0). Median progressive-free survival (PFS) was 5.6 months (95% CI, 4.3-6.6), and median overall survival (OS) was 10.3 months (95% CI, 8.8-12.3). Treatment-related adverse events of grade ≥3 were reported in 27 (48.2%) patients with the most common being decreased neutrophil count. Patients with PD-L1 TPS ≥1% showed a higher ORR (66.7% vs. 25.0%), as well as longer median PFS (6.3 vs. 5.3 months) and median OS (18.8 vs. 9.9 months). Fibrosis-associated signatures (such as ECM-myCAF and IL-iCAF) and pSMAD2/3 level were associated with anti-tumor activity.
Conclusions
SHR-1701 combined with AG showed positive antitumor activity and controllable safety in advanced pancreatic cancer.
Clinical trial identification
NCT04624217.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1445P - Novel DNA methylation markers for early detection of cardia gastric adenocarcinoma and esophageal squamous cell carcinoma
Presenter: Zhiyuan Fan
Session: Poster session 18
Resources:
Abstract
1446P - Efficacy and safety of cadonilimab combined albumin-paclitaxel, cisplatin and fluorouracil (APF) in neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): Results from the CAPITAL trial
Presenter: Huiwen Miao
Session: Poster session 18
Resources:
Abstract
1447P - Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
Presenter: David Tougeron
Session: Poster session 18
Resources:
Abstract
1448P - IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts
Presenter: Christelle de la Fouchardiere
Session: Poster session 18
Resources:
Abstract
1449P - Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
Presenter: Markus Moehler
Session: Poster session 18
Resources:
Abstract
1450P - Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial
Presenter: Georg Martin Haag
Session: Poster session 18
Resources:
Abstract
1451P - Neoadjuvant and adjuvant pembrolizumab (pembro) + chemotherapy (chemo) for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer: Patient-reported outcomes (PROs) from the phase III KEYNOTE-585 study
Presenter: Kohei Shitara
Session: Poster session 18
Resources:
Abstract
1452P - Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1ST-RT): A single-arm, open-label, phase II trial
Presenter: Wei Huang
Session: Poster session 18
Resources:
Abstract
1453P - A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)
Presenter: Nan Bi
Session: Poster session 18
Resources:
Abstract
1454P - An open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001)
Presenter: Akihito Kawazoe
Session: Poster session 18
Resources:
Abstract